KRYS - יחס חוב להיוון בספרים Krystal Biotech Inc

Krystal Biotech, Inc. (KRYS) is expanding within its own product cycle, ensuring a sharp surge in revenue regardless of economic conditions. The company targets patients with severe genetic skin pathologies, receiving payments from insurance providers. This price chart, where the indicator stands at 0.01, complements the profile of a brand recognized by physicians for innovations in gene therapy and the creation of unique therapeutic gels.

For Krystal Biotech, Inc. (KRYS), the ratio of total liabilities to the book value of assets determines the stability of financial leverage amid the rapid commercialization of Vyjuvek. By analyzing the debt-to-enterprise value profile, investors assess the proportion of borrowed capital within the balance sheet structure, allowing them to differentiate operational growth from credit risks during shifts in market cycles.